Epstein-Barr Virus-Latent Membrane Protein 1 Expression Has a Favorable Influence in the Outcome of Patients with Hodgkin's Disease Treated with Chemotherapy

References

• Aisenberg A C. Problems in Hodgkin's disease management. Blood 1999; 93: 761–779
   PubMed Web of Science ®Google Scholar
• Bonadonna Santoro G. A. ABVD chemotherapy in the treatment of Hodgkin's disease. Cancer Treat Rev. 1982; 9: 21–35
   PubMed Web of Science ®Google Scholar
• Canellos G P, Anderson J R, Propert K J, et al. Chemotherapy of advanced Hodgkin's disease with MOPP. ABVD. or MOPP alternating: with ABVD. N Eng J Med 1992; 327: 1478–84
   PubMed Web of Science ®Google Scholar
• Bonfante V, Santoro A, Viviani S, et al. ABVD in the treatment of Hodgkin's disease. Semin Oncol 1992; 19: 38–45
   PubMedGoogle Scholar
• Santoni A, Bonadonna G, Bonfante V, et al. Alternating Drug combinations in the treatment of advanced Hodgkin's disease. N Eng J Med 1982; 306: 770–775
   PubMed Web of Science ®Google Scholar
• Viviani S, Bonadona G, Santoro A, et al. Alternating versus hybrid MOPP and ABVD combination in advanced Hodgkin's disease: ten years results. J Clin Oncol 1996; 5: 1421–1430
   Google Scholar
• Dihel V, Franklin J, Hanseclever D, et al. BEACOPP. a new reginten for advanced Hodgkin's disease. Ann Oncol 1998; 9(Suppl 5)S67–S71
   PubMedGoogle Scholar
• Bartlett N L, Rosemberg S A, Hoppe R T., et al. Brief chemotherapy, Stanford V. and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report. J Clin Oncol 1995; 13: 1080–1088
   PubMed Web of Science ®Google Scholar
• Bhidayasira Linch R. D. High dose therapy for Hodgkin's disease. Blood Reviews 1999; 13: 45–50
   PubMed Web of Science ®Google Scholar
• Straus D J, Gaynor Myers J J, et al. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially non-cross-resistant chemotherapy and intermediate-dose radiation therapy. J Clin Oncol 1990; 8: 1173–1186
   PubMed Web of Science ®Google Scholar
• Mauch P, Larson D, Osteen R, et al. Prognostic factors for positive surgical staging in patients with Hodgkin's disease. J Clin Oncol. 1990; 8: 257–265
   PubMed Web of Science ®Google Scholar
• Specht L, Nordentoft A M, Cold S, et al. Tumor burden as the most important prognostic factor in early stage Hodgkin's disease. Cancer 1988; 61: 1714–1727
   Web of Science ®Google Scholar
• Tubiana Henry M., Amar M, Carde P, et al. Toward comprehensive management tailored to prognostic factors of patients with clinical stage I and II in Hodgkin's disease. The ORTC Group Controlled Clinical Trials 1964–1987. Blood 1989; 73: 47–56
   PubMed Web of Science ®Google Scholar
• Henry-Amar M, Friedman S, Ayat M, et al. Erythrocyte sedimentation rate predicts early relapse and survival in early-stage Hodgkin's disease. Ann Intern Med 1991; 114: 361–365
   PubMed Web of Science ®Google Scholar
• Dimopoulos M A, Cabanillas F, Lee J J., et al. Prognostic role of serum beta 2-microglobulin in Hodgkin's disease. J Clin Oncol 1993; II: 1108–1111
   Google Scholar
• Longo D L, Glatstein Duffey E. PL, et al. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's discase. Blood 1997; 15: 3338–3346
   Google Scholar
• Sarris A H, Kliche K-Pethambaram O. P., et al. Inter-Icukin-10 levels arc often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival. Ann Oncol 1999; 10: 433–440
   PubMed Web of Science ®Google Scholar
• Nadali G, Tavecchia L, Zanolin E, et al. Serum level of the soluble form of CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome. Blood 1998; 91: 3011–3016
   PubMed Web of Science ®Google Scholar
• Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. N Eng J Med 1998; 339: 1506–1514
   PubMed Web of Science ®Google Scholar
• Oudejans J J, Jiwa N M, Kummer J A, et al. Activated cytotoxic T-cells as prognostic marker in Hodgkin's disease. Blood 1997; 89: 1376–1382
   PubMed Web of Science ®Google Scholar
• Xerri L, Boubdallah R, Camerlo J, Hassoun J. Expression of the p53 gene in Hodgkin's disease: dissociation between immunohistochemistry and clinicopathological data. Hum Pathol 1994; 25: 449–454
   PubMed Web of Science ®Google Scholar
• Brink A ATP, Oudejans J J, van den Brule A JC, et al. Low p53 and high bcl-2 expression in Reed-Sternberg cells predict poor clinical outcome for Hodgkin's disease: involvement of apoptosis resistance?. Mod Pathol 1998; 11: 376–383
   PubMed Web of Science ®Google Scholar
• Sarris A H, Medeiros U, Khorana S, et al. Bcl-2 is frequently expressed in Hodgkin-Reed-Sternberg cells and is associated with inferior failure-free survival in Hodgkin's disease treated with ABVD. Ann Oncol 1999; 10(suppl 3)72a
   Google Scholar
• Claviez A, Tiemann M, Peters J, Kreipe H, Schneppenheim P, Parwaresch R. The impact of EBV, proliferation rate and bcl-2 expression in Hodgkin's disease in childhood. Ann Hematol 1994; 68: 61–66
   PubMed Web of Science ®Google Scholar
• Fellbaum C, Hansmann M L, Niedemeyer H, et al. Influence of Epstein-Barr virus genomes on patient survival in Hodgkin's disease. J Clin Pathol 1992; 98: 319–323
   Web of Science ®Google Scholar
• Naresh K N, Johnson J, Srinivas V, et al. Epstein-Barr virus association in classical Hodgkin's disease provides survival advantage to patients and correlates with higher expression of proliferation markers in Reed-Stemberg cells. Ann Oncol 2000; 11: 91–96
   PubMed Web of Science ®Google Scholar
• Sarris A H, Medeiros L J, Herling M, et al. The expression of the EBV-coded latent membrane protein-I (LMP-I) in Reed-Stemberg cells of Hodgkin's disease (HD) is associated with higher serum IL-10 levels and inferior failure-free survival (FFS). Blood 1998; 92(suppl 1)353a
   PubMed Web of Science ®Google Scholar
• Murray P G, Billingham L J, Hassan H T, Flavell J R, Nelson P N, et al. Effect of Epstein-Barr virus infection on response to chemotherapy and survival in Hodgkin's disease. Blood 1999; 94: 442–447
   PubMed Web of Science ®Google Scholar
• Morente M, Piris M A, Abraira V, et al. Adverse clinical outcome in Hodgkin's disease is associated with loss of retinoblastoma protein expression. high Ki67 proliferation index, and absence of Epstein-Barr virus-latent protein I expression. Blood 1997; 90: 2429–2436
   PubMed Web of Science ®Google Scholar
• Martinez-Montero J C, Pins M A, Sanchez-Beato M, et al. Retinoblastoma (Rb) gene product expression in lymphomas. Correlation with ki67 growth fraction. J Pathol 1993; 169: 405–412
   PubMed Web of Science ®Google Scholar
• Sanchez Beato M, Martinez Montero J C, Doussis-Anagnostopoulou I A, et al. Anomalous retinoblastoma protein expression in Stemberg-Reed cells in Hodgkin's disease: A comparative study with p53 and ki67 expression. Br J Cancer 1996; 74: 1056–1062
   PubMed Web of Science ®Google Scholar
• Lee E T. Statistical Methods for Survival Data Analysis. lifetime Learning Publications, Belmont 1980
   Google Scholar
• Kleinbaum D G, Kupper L L, Morgenstern H. Epidemiologic Research. Principles and Quantitative Methods. Van Nostrand Reinhold, New York 1982
   Google Scholar
• Belsley D A. Conditioning diagnosis: colinearity and weak data in regression. John Willey & Sons, New York 1991
   Google Scholar
• Abraira Zaplana V. J. PRESTA: Un paquete de proce-samientos estadisticos. Resumenes de la Conferencia Iber-americana de Bioingeniería. Gijon 1984; 101
   Google Scholar
• Loeffler M, Brosteanu O, Hasenclever D, et al. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. J Clin Oncol 1998; 16: 818–829
   PubMed Web of Science ®Google Scholar
• Rickinson A B, Murray R J, Brooks J, Griffin H, Moss D J, Massucci M G. T-cell recognition of Epstein-Barr virus associated lymphomas. Cancer Surv, 13: 53–79
   PubMedGoogle Scholar
• Okan I, Wang Y, Chen F, et al. The EBV-encoded LMPI protein inhibits p53-triggered apoptosis but not growth arrest. Oncogene 1995; 11: 1027–31
   PubMed Web of Science ®Google Scholar